Kaoru Tsuchiya
Overview
Explore the profile of Kaoru Tsuchiya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
2229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kodama Y, Ueshima K, Moriguchi M, Inaba Y, Yamashita T, Iwamoto H, et al.
BMC Cancer
. 2025 Mar;
25(1):434.
PMID: 40069616
Background: Atezolizumab plus bevacizumab is recommended as a first-line treatment for unresectable hepatocellular carcinoma (uHCC). A subgroup analysis of the IMbrave150 trial showed shorter overall survival (OS) in uHCC patients...
2.
Aoki T, Kudo M, Nishida N, Ueshima K, Tsuchiya K, Tada T, et al.
J Gastroenterol
. 2025 Mar;
PMID: 40055288
Background: Achieving complete response (CR) is a desirable goal in early-to-intermediate-stage hepatocellular carcinoma (HCC). While systemic and locoregional therapies show promise, optimal drug discontinuation criteria remain unclear. This study aims...
3.
Ochi H, Kurosaki M, Tanaka T, Tamaki N, Tsuchiya K, Yasui Y, et al.
JGH Open
. 2025 Jan;
9(1):e70098.
PMID: 39834908
Aim: We investigated the impact of proteinuria on the therapeutic effect before lenvatinib administration as second-line treatment after atezolizumab-bevacizumab. Methods: We examined 64 patients who were administered lenvatinib as second-line...
4.
Kudo M, Tsuchiya K, Yamashita T, Koga H, Nakagawa Y, Ikeda M
Liver Cancer
. 2024 Dec;
13(6):671-673.
PMID: 39687035
No abstract available.
5.
Mori N, Tamaki N, Takaki S, Tsuji K, Tada T, Nakamura S, et al.
Invest New Drugs
. 2024 Aug;
42(5):559-565.
PMID: 39212893
Although immune checkpoint inhibitors (ICI) are used for unresectable hepatocellular carcinoma (HCC), it is unclear whether sequential ICI treatment-durvalumab plus tremelimumab (DT) after progression on atezolizumab plus bevacizumab (AB)-is effective...
6.
Tamaki N, Mori N, Takaki S, Tsuji K, Tada T, Nakamura S, et al.
Anticancer Res
. 2024 Aug;
44(9):3913-3918.
PMID: 39197893
Background/aim: Maintaining liver function throughout the treatment of hepatocellular carcinoma (HCC) is crucial, yet the impact of durvalumab plus tremelimumab (DT) treatment on liver function is not well understood. This...
7.
Kudo M, Tsuchiya K, Shao Y, Finn R, Galle P, Ducreux M, et al.
Liver Cancer
. 2024 Aug;
13(4):401-412.
PMID: 39114762
Introduction: The phase III IMbrave150 study established atezolizumab + bevacizumab as the global standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis examined the impact of...
8.
Tamaki N, Takaura K, Higuchi M, Yasui Y, Itakura J, Tsuchiya K, et al.
Diagnostics (Basel)
. 2024 Jul;
14(13).
PMID: 39001207
The enhanced liver fibrosis (ELF) score is a blood test that combines three markers linked to liver fibrosis. The utility of the ELF score has been demonstrated primarily in Western...
9.
Kobayashi K, Ogasawara S, Itobayashi E, Okubo T, Itokawa N, Nakamura K, et al.
Invest New Drugs
. 2024 Jun;
42(4):394-404.
PMID: 38842657
This study aimed to complement the results of the REACH-2 study by prospectively evaluating the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma (HCC) in a real-world setting. This...
10.
Ikeda M, Yamashita T, Ogasawara S, Kudo M, Inaba Y, Morimoto M, et al.
Liver Cancer
. 2024 May;
13(2):193-202.
PMID: 38751550
Introduction: Hepatic arterial infusion chemotherapy (HAIC) with cisplatin and lenvatinib exhibits strong antitumor effects against advanced hepatocellular carcinoma (HCC). Higher antitumor activity is expected for the combination treatment. The aim...